Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Triple Negative Breast Neoplasms × olaparib × Clear all

Phase

Status

Sponsor Class

OTHER 13 INDUSTRY 6 NIH 2 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 2 Triple Negative Breast Neoplasms 1 Rectal Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Bone Neoplasms 1

Interventions

Cyclophosphamide 2 olaparib 1 fludarabine 1 durvalumab 1 atezolizumab 1 Methotrexate 1 Cisplatin 1 Carboplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡